Lucid Diagnostics (LUCD) Expected to Announce Earnings on Monday

Lucid Diagnostics (NASDAQ:LUCD) is expected to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Lucid Diagnostics Price Performance

LUCD stock opened at $1.39 on Monday. The business has a fifty day moving average price of $1.14 and a 200 day moving average price of $0.96. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63. The stock has a market capitalization of $82.49 million, a price-to-earnings ratio of -1.22 and a beta of 1.34.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets dropped their price target on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Lucid Diagnostics presently has an average rating of “Buy” and a consensus price target of $3.63.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.